Shenaz Bagha

NASHVILLE, Tenn. — Among children with ulcerative colitis, mirikizumab achieved clinical and endoscopic remission rates exceeding those of historical adult outcomes with placebo at week 12, according to data presented.

Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type LIVE

NASHVILLE, Tenn. — Antidrug antibodies did not appear to negatively affect outcomes in patients with inflammatory bowel disease after initiation of subcutaneous infliximab following a “drug holiday,” according to a presenter.

Dietary supplement use is “extremely common” in patients with lupus, with nearly 30% taking at least one supplement-medication combination with a potential interaction, according to data published in Arthritis Care & Research.

SAN DIEGO — Patients with severe symptoms of long COVID experienced relief with 12 weeks of Bezisterim therapy, according to a poster presented at the 151st Annual Meeting of the American Neurological Association.

NASHVILLE, Tenn. — Tezepelumab significantly improved histologic remission and dysphagia symptoms at 24 and 52 weeks compared with placebo among individuals with eosinophilic esophagitis, according to a presenter.

NASHVILLE, Tenn. — Tegoprazan demonstrated significant improvements in 24-hour and nighttime heartburn among patients with nonerosive reflux

Data linking estrogen-only therapy for menopausal women to a modest increase in autoimmune disease risk, vs. estrogen-plus-progestogen, reinforce

SAN DIEGO — Patients with Huntington's disease with chorea experienced improvements through 5 years of treatment with valbenazine, according to a

NASHVILLE, Tenn. — Patients with ileal Crohn's disease had significantly better clinical and endoscopic outcomes at week 54 with subcutaneous vs.